Donanemab

  • A new drug called Donanemab has been hailed as a breakthrough in the world of health, providing hope for people suffering from Alzheimer's disease.
  • Donanemab, developed by Eli Lilly, has shown significant promise in slowing cognitive and functional decline in patients with early-stage Alzheimer's disease.
  • The drug is a monoclonal antibody that targets amyloid, a sticky protein that damages neurons in the brains of people with dementia.
  • The development of Donanemab holds potential for transforming the treatment landscape for this debilitating brain ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

News Snippets